Sep 25-26, 2025

Guangzhou・China

The Guangdong-Hong Kong-Macao Greater Bay Area is a hotbed for the research and development of gene cell therapy. In addition to many high-quality companies, there are also a large number of universities, high-quality hospitals, and global research institutes. Research institutes and hospitals undertake most of the early research of innovative drugs. Many excellent projects are transformed from scientific and technological achievements. Many domestic pharmaceutical companies have completed early research in research institutes. The Medical Technology Transformation Committee of the Guangdong Research Hospital Association aims to build a medical research and production integration platform. At present, the committee has established an organizational structure, established rules and regulations, and plans to carry out work with five major tasks such as academic exchanges and scientific and technological innovation as the core, and promote the industrialization of scientific research results through closed-door meetings on technical achievements.

In order to promote the transformation of scientific and technological achievements of the member units of the Transformation Committee and provide accurate auxiliary judgment and direction guidance for the proposed transformation of scientific and technological projects, we have cooperated with the organizer of the 2025 Third Greater Bay Area Cell Gene Therapy Development Forum to organize a closed-door meeting on the transformation of scientific and technological achievements in colleges and universities. This closed-door meeting plans to invite investment institutions, CROs, CDMOs, CSOs, BDs of large pharmaceutical companies, R&D leaders of large pharmaceutical companies, founders of large pharmaceutical companies and other industry-related companies to gather together to accurately diagnose the proposed transformation companies, so that everyone can hear real feedback from different industry perspectives, know the real voices of industry experts, and provide multi-dimensional references for your transformation projects, helping your projects to be more smooth on the road to transformation.

Who should  attend

Investment, CXO, MNC, universities, research institutions, hospitals, etc.

Who already registered

Topgenebio | Portonbio | genevoyager | lewwin Pharm | Bojimed | Oricellbio | landau bio | JOINN Laboratories | cantonbio | Zhongke stemcell | Saifu Lab | Guangzhou Industry Investment Holding | Kaide Capital | Pine VC | Legend Capital | Chuangyu Investment | Yuekai Capital | Redhill Capital,etc

Organizer: Medical Technology Transformation Committee of Guangdong Provincial Research Hospital Association

Co-Organizer: Xperiobio, Yingke (Guangzhou) Law Firm

Time: September 26, 2025, morning (Friday)

Location: 2 Floor, Closed-door conference room, Guangzhou Knowledge City International Convention and Exhibition Center

Projects Discription

1.Highly Organ- and Tumor Cell-Specific Oncolytic Virus

The project is an internationally leading therapeutic drug for liver cancer. This project was established by Professor Gao Feng's team and possesses the following distinctive features and advantages:

1. The world's first oncolytic herpes simplex virus (oHSV) with tumor-specific replication and highly efficient tumor-killing capability;

2. A pioneering liver-targeting delivery system enables precise intravenous administration of the oncolytic virus to liver tumors;

3. Addresses the significant unmet medical need in hepatocellular carcinoma (HCC) treatment in China, with broad clinical potential;

4. The oncolytic herpes simplex virus platform has already been approved for clinical use, ensuring proven efficacy and safety.

2.In Situ Brain Neuroregeneration Gene Therapy

This is an internationally leading therapeutic drug for central nervous system (CNS) death-related diseases, such as stroke and Alzheimer’s disease, developed by Professor Chen Gong. Key features and advantages include:

1. The world's first in situ neural regenerative gene therapy, featuring precise treatment, high efficiency and low cost (~10,000 RMB/patient);

2.Utilizes AAV (adeno-associated virus) - the gold standard vector for gene therapy - to deliver neural transcription factors, demonstrating strong universality for treating multiple patient types;

3.Addresses enormous unmet clinical needs including stroke, Alzheimer's disease, traumatic brain injury, glioma, and other CNS disorders;

4.Excellent safety profile: enables in situ regeneration of functional neurons with low dosage and minimal side effects.

3.High-Throughput Engineered Microfluidic Organoid Platform Project

This is a domestically advanced organoid solution for personalized treatment and drug screening of complex tumors and regenerative diseases, developed by Professor Ma Shaohua's team at Tsinghua University. Key features and advantages include:

1. World's first organoid 3D bioprinting + microfluidic manufacturing technology, increasing efficiency by 10-100x while significantly reducing construction costs;

2. Requires only minimal clinical samples (<5 μL) for modeling, compatible with allogeneic tissue high-throughput preparation;

3. Addresses critical clinical gaps in precision medication and rare disease modeling, achieving "modeling + drug screening + recommendation" within 9 days;

4. Equipment has entered mass production and been adopted by top global pharmaceutical companies and tier-3 hospitals, honored with the Geneva International Invention Award;

5. Enables "AI + organoid" drug discovery paradigm, accelerating new drug development and precision therapy implementation.

4. Stem Cells and Inner Ear Injury Repair

The project team has systematically investigated and elucidated the pathogenesis of acquired hearing disorders. Based on the unique structure of the inner ear and considering the limitations of existing therapies, the research findings have been published in prestigious academic journals including PNAS, Materials Today Bio, Biomedicine & Pharmacotherapy, and Hearing Research.

5. Next-generation engineered stem cell therapy

1. Advancing Stem Cell Therapy Innovation

We are pioneering molecular engineering technologies to revolutionize stem cell therapies, developing novel cell-based solutions for complex diseases. Our proprietary DNA Hybridization Chain Reaction (HCR) technology enables precise modification of cell surfaces with mono- or multi-valent targeting molecules, significantly enhancing tissue-specific homing capabilities.

2. Robust Therapeutic Pipeline

Three investigational stem cell drug candidates are currently in preclinical proof-of-concept (POC) stage, targeting refractory diseases including heart failure.

Close-door Meeting: Free Registration (25 Seats available, Approval Required)

Successful applicants will receive confirmation via email & SMS.

send application to：Ms Wei

Mobile and wechat:+86 152 1686 1311

Email: marketing@xperiobio.com